Albumin Or Derivative Affecting Or Utilizing Patents (Class 514/15.2)
  • Patent number: 10420922
    Abstract: This disclosure relates to swellable needles that include a proximal end portion and a swellable distal end portion. Upon exposure to a liquid, the needles are configured to undergo a shape change from a first configuration in which the width of the needle is tapered from the proximal end portion to the distal end portion to a second configuration in which the distal end portion is more swollen than the proximal end portion. The swellable needles can be double layer swellable needles or single material swellable needles.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: September 24, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Seung Yun Yang, Jeffrey M. Karp, Eoin D. O'Cearbhaill, Bohdan Pomahac
  • Patent number: 9926570
    Abstract: The present invention relates to genetically modified host cells, in particular yeast cells, comprising at least one isolated polynucleotide encoding a Killer Expression protease (Kex2p) or a fragment and/or variant thereof which has at least one Kex2p functional activity and at least one isolated polynucleotide encoding a Protein Disulfide-Isomerase (Pdi1) or a fragment and/or variant thereof which has at least one Pdi functional activity.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: March 27, 2018
    Assignee: GlaxoSmithKline LLC
    Inventors: Yonghwan Jin, Yuan Zhu
  • Patent number: 9889085
    Abstract: The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: February 13, 2018
    Assignee: INTARCIA THERAPEUTICS, INC.
    Inventors: Thomas R. Alessi, Michelle Baron
  • Patent number: 9707176
    Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates where appropriate.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: July 18, 2017
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Anette Brunner-Schwarz, Werner Mueller, Verena Siefke-Henzler
  • Patent number: 9629920
    Abstract: The invention features a powdered composition including a pharmaceutically active compound and a protein or a hydrolyzed protein. In particular, the powdered composition forms a stable solution or dispersion suitable for oral administration in which the protein or the hydrolyzed protein is bound to the pharmaceutically active compound. The invention also provides a method of administering the composition, such as to a patient with dysphasia; liquid or semi-solid formulations of the composition; methods for preparing the composition; and kits including the composition.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: April 25, 2017
    Assignee: Exodos Life Sciences Limited Partnership
    Inventors: Harry J. Leighton, Crist J. Frangakis
  • Patent number: 9629904
    Abstract: A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: April 25, 2017
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Patent number: 9498521
    Abstract: Preparations of Clostridium botulinum neurotoxin BoNT/A3 and methods for using such preparations for treating a patient having a symptom in need of botulinum toxin therapy are provided herein.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: November 22, 2016
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Eric Johnson, William Tepp, Guangyun Lin
  • Patent number: 9394339
    Abstract: Stabilization of water-containing solutions or lyophilizates of proteins and peptide against non-enzymatic deamidation degradation reactions at asparaginyl or glutaminyl residues is achieved using organic anions, such as saccharin, benzenesulfonic acid, gentisic acid or N-acetyltryptophan which have a pKa within the range of 0.5 to 3.5.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: July 19, 2016
    Assignee: Lyotropic Therapeutics, Inc.
    Inventor: David Anderson
  • Patent number: 9078892
    Abstract: An acute pain medication overuse disorder (such as a medication overuse headache disorder) can be treated by administration of a botulinum toxin to a patient. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: July 14, 2015
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Mitchell F. Brin
  • Patent number: 9050336
    Abstract: Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: June 9, 2015
    Assignee: Allergan, Inc.
    Inventors: Wendy M. Blanda, Roger K. Aoki, Terrence J. Hunt, Patrick M. Hughes, James N. Chang, Scott M. Whitcup, Michael R. Robinson
  • Patent number: 9045564
    Abstract: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: June 2, 2015
    Assignee: MedImmune, LLC
    Inventors: Changshou Gao, Chaity Chaudhury, Xiaotao Yao
  • Patent number: 9044477
    Abstract: Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: June 2, 2015
    Assignee: Allergan, Inc.
    Inventors: Wendy M. Blanda, Roger K. Aoki, Terrence J. Hunt, Patrick M. Hughes, James N. Chang, Scott M. Whitcup, Michael R. Robinson
  • Publication number: 20150147320
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Application
    Filed: December 16, 2014
    Publication date: May 28, 2015
    Inventors: SHEUE-FANG SHIH, PO-CHUN CHANG, YUN-LONG TSENG, LUKE S.S. GUO, KEELUNG HONG
  • Publication number: 20150147324
    Abstract: This invention relates to fusion proteins that include a whey acidic protein (WAP) domain-containing polypeptide and a second polypeptide. Additionally, the invention relates to fusion proteins that include a WAP domain-containing polypeptide a second polypeptide, and a third polypeptide. The second and/or third polypeptides of the fusion proteins of the invention are a Fe polypeptide; an albumin polypeptide; a cytokine targeting polypeptide; or a serpin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: John C. Timmer, Brendan P. Eckelman, Grant B. Guenther, Peter L. Nguy, Henry Chan, Quinn Deveraux
  • Publication number: 20150147325
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • Publication number: 20150141342
    Abstract: The differential expression of select miRNA in plasma and bile among patients with PDAC, chronic pancreatitis (CP), and controls were measured. Patients (n=215) with treatment-naïve PDAC (n=77), CP with bile or pancreatic duct pathology (n=67), and controls (n=71) that had been prospectively enrolled in a Pancreatobiliary Disease Biorepository at the time of endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS) were identified. Controls were patients with choledocholithiasis but normal pancreata. The sample was separated into training (n=95) and validation (n=120) cohorts to establish and then test the performance of PDAC Signature Panels in diagnosing PDAC. The training cohort (n=95) included age-matched patients with CP and controls. Panels were derived from the differential expression of 10-candidate miRNA in plasma or bile.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: Murray Korc, A. Jesse Gore, Gregory A. Cote, Stuart Sherman
  • Publication number: 20150141343
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Publication number: 20150139944
    Abstract: Provided is a separatome-based recombinant peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome, such as that of E. coli, yeast, Bacillus subtilis or other prokaryotes, insect cells, mammalian cells, etc. This platform quantitatively describes and identifies priority deletions, modifications, or inhibitions of certain gene products to increase chromatographic separation efficiency, defined as an increase in column capacity, column selectivity, or both, with emphasis on the former. Moreover, the platform provides a computerized knowledge tool that, given separatome data and a target recombinant peptide, polypeptide, or protein, intuitively suggests strategies leading to efficient product purification.
    Type: Application
    Filed: October 23, 2014
    Publication date: May 21, 2015
    Inventors: Ellen M. Brune, Robert R. Beitle, Mohammad M. Ataai, Patrick R. Bartlow, Ralph L. Henry
  • Publication number: 20150125391
    Abstract: Bone- and metal-targeted polymeric nanoparticles are provided. Exemplary nanoparticles have three main components: 1) a targeting element that can selectively bind to bone, minerals, or metal ions; 2) a layer of stealth to allow the polymer to evade immune response; and 3) a biodegradable polymeric material, forming an inner core which can carry therapeutics or other diagnostics. Preferred nanoparticles contain a blend of target-element polymer conjugate and polymer that optimizes the ligand density on the surface of the nanoparticle to provide improved targeting of the nanoparticle. The ratio of target-element polymer conjugate to polymer can also be optimized to improve the half-life of the nanoparticles in the blood of the subject. The nanoparticles also exhibit prolonged, sustained release of therapeutic agents loaded into the particles.
    Type: Application
    Filed: November 3, 2014
    Publication date: May 7, 2015
    Inventors: Archana Swami, Pamela Basto, Jeffrey Karp, Omid C. Farokhzad
  • Patent number: 9023797
    Abstract: Described herein are methods for inactivating viruses using caprylate in solutions containing albumin.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: May 5, 2015
    Assignee: Grifols, S.A.
    Inventors: Wytold Lebing, Doug Burns, Nathan Roth, Joann Hotta
  • Publication number: 20150112244
    Abstract: Otologic materials and methods are provided. For example, a cell-adhesive, biodegradable hydrogel scaffold loaded with time-released drugs for repairing chronic tympanic membrane perforations is disclosed, methods of making same and administering same are provided. This hydrogel may promote vascular in-growth and epithelial cell growth of the tympanic membrane with the purpose of closing the perforation and providing a barrier between the external and middle ear. The hydrogel is initially a liquid polymer that only gels upon exposure to specific conditions, such as exposure to light. This scaffold may simultaneously induce repair of the tympanic membrane while preventing or alleviating middle ear infection, thus filling a void in current tympanic membrane perforation therapies.
    Type: Application
    Filed: December 28, 2014
    Publication date: April 23, 2015
    Applicant: The Administrators of the Tulane Educational Fund
    Inventors: Elaine Horn-Ranney, Parastoo Khoshakhlagh, Michael Moore, Jesse Ranney
  • Publication number: 20150098985
    Abstract: A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme, wherein the activities of both the wound healing therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a would fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP).
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Inventors: BREDA MARY CULLEN, SARA JAYNE GREGORY
  • Publication number: 20150087586
    Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise conjugated C-peptide derivatives which exhibit superior pharmacokinetic and biological activity in vivo.
    Type: Application
    Filed: March 25, 2013
    Publication date: March 26, 2015
    Inventors: Sheri Barrack, James Callaway, Michelle Mazzoni
  • Publication number: 20150080310
    Abstract: A biocompatible composition which comprises crosslinkable serum albumin, crosslinkable serum protein and/or crosslinkable derivatives derived therefrom, and which is polymerizable to give a hydrogel-forming material, is used in a method for the prevention of pathological adhesions.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Larissa Lehmann, Elke Rist, Beate Scholz, Burkhard Schlosshauer, Juergen Mollenhauer, Christoph Gaissmaier
  • Publication number: 20150079181
    Abstract: The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Applicant: Abraxis BioScience, LLC
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG
  • Publication number: 20150079156
    Abstract: The present invention is directed to a liposomal delivery system comprising defined lipid components, including dimethyldioctadecylammonium and other lipid components and a stabilizing agent, which may be used in the delivery of bioactive agents to a subject in need thereof. The liposomal delivery system of the invention provide improvements in terms of delivery and stability. Ideally, the liposomal delivery system is used as a vaccine or drug/medicament delivery system although other bioactive agents may be delivered.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Inventors: Victoria Kett, Helmy Yusuf, Helen McCarthy, Kun Hung Chen
  • Publication number: 20150072928
    Abstract: The apparatus and methods of the present invention are of use for the production of emulsion-based microparticles containing a biological or chemical agent. In particular, the apparatus provides a vessel; packing material situated inside such vessel and may further provide material capable of insertion into both ends of said vessel for enclosure of the packing material. In a particular embodiment, the apparatus is a packed bed apparatus. The methods include production of emulsion based microparticles containing a biological or chemical agent. The usefulness of the present invention is that the apparatus and methods of the present invention provide for a low-shear, non-turbulent, production of emulsion-based microparticles that provides a narrow, reproducible, particle size distribution, capable of use with both large and small volumes that is capable of being conveniently scaled up while providing predictable emulsion properties.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Inventor: Ehud Zeigerson
  • Publication number: 20150071879
    Abstract: An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).
    Type: Application
    Filed: October 17, 2014
    Publication date: March 12, 2015
    Inventor: Jan JEZEK
  • Publication number: 20150071997
    Abstract: Methods of encapsulating cargo in a microgel droplet, microgel droplets prepared according the provided methods, and methods of use thereof are disclosed. The methods of preparing cargo-encapsulated microgels generally include flowing through a flow-focusing nozzle of a microfluidic device a macromer phase, an oil phase, and a crosslinker phase to form microgel droplets by oil-water emulsion. The phases are pumped, injected, or flowed through the microfluidic device such that as the macromer phase approaches the flow focusing nozzle, the co-flowing oil phase shields the macromer from contact with the crosslinker phase until flow instability occurs and macromer phase droplets form. After flow instability occurs, the crosslinker diffuses from the crosslinker phase into the droplets in an effective amount to covalently crosslink the macromer into a microgel network encapsulating the cargo in the crosslinked macromer.
    Type: Application
    Filed: September 9, 2014
    Publication date: March 12, 2015
    Inventors: Andres Garcia, Devon Headen, Edward A. Phelps, Guillaume A. Aubry, Hang Lu, Cristina Gonzalez Garcia
  • Publication number: 20150044280
    Abstract: The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor or inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 12, 2015
    Applicant: Vascular Biogenics Ltd.
    Inventors: Eyal BREITBART, Andrea Leubitz, Erez Feige, Richard Penson
  • Publication number: 20150038415
    Abstract: Process for the manufacturing of a drug delivery system based on a polymer comprising dispersed bioactive agent via the following process steps: (a) dissolving a polymer in an organic solvent (b) mixing the dissolved polymer with the bioactive agent (c) laminating the mixture between two polymer sheets, whereby at least one of the sheets is permeable to the organic solvent, to provide a film whereby the film can be further processed into the drug delivery system. The drug delivery system is suitable for implantation or injection and comprises fibres, rods, discs, coatings, tubes, films or rolled films.
    Type: Application
    Filed: December 14, 2012
    Publication date: February 5, 2015
    Inventor: John Andrew Zupancich
  • Patent number: 8946167
    Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: February 3, 2015
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
  • Publication number: 20150030642
    Abstract: The invention discloses a polymer micro-needle array chip, comprising a substrate and a micro-needle array standing thereon; the material for preparing the micro-needle array is a polyacrylamides polymer, with the molecular weight of 1.0×104-2.0×105, the Vickers hardness of 150-600 HV, and the impact strength of 5-30 J/m. The polymer micro-needle array chip has a high mechanical strength and a sharp needle tip, and it can easily dissolve or swell on contact with a water-containing environment, which helps the drug to be released slowly in the skin.
    Type: Application
    Filed: May 25, 2012
    Publication date: January 29, 2015
    Applicant: Technical Institute of Physics and Chemistry of the Chinese Academy of Sciences
    Inventors: Feipeng Wu, Yuanhua Miao
  • Publication number: 20150030686
    Abstract: Toroidal-spiral shaped particles, their method of manufacture, and uses thereof are disclosed. The toroidal-spiral particles can contain at least one active agent, such as a drug, and provide a controlled, sustained release of the active agent.
    Type: Application
    Filed: August 11, 2014
    Publication date: January 29, 2015
    Inventors: Ludwig C. Nitsche, Ying Liu
  • Publication number: 20150025012
    Abstract: Provided herein are methods, assays and kits for evaluating a sample, e.g., a sample obtained from a cancer patient, to detect one or more hedgehog biomarkers and/or one or more cilium markers. Thus, the invention can be used, inter alia, as a means to identify patients likely to benefit from administration of one or more hedgehog inhibitors, alone or in combination with therapeutic agents; to predict a time course of disease or a probability of a significant event in the disease of a cancer patient; to stratify patient populations; and/or to more effectively treat or prevent a cancer or a tumor associated with hedgehog signaling.
    Type: Application
    Filed: August 8, 2014
    Publication date: January 22, 2015
    Inventors: John R. MacDougall, Juan Guillermo Paez, Karen J. McGovern, Jeffery L. Kutok, Georgios Skliris, Kerry White, Kerrie L. Faia, Marisa Osswalt Peluso, Veronica Travaglione Campbell
  • Publication number: 20150023977
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 22, 2015
    Applicant: ABBVIE INC.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Publication number: 20150023960
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Application
    Filed: March 8, 2013
    Publication date: January 22, 2015
    Inventors: Darrin Anthony Lindhout, Peng Zhang, Thomas Frederick Parsons
  • Publication number: 20150023912
    Abstract: The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 22, 2015
    Inventors: Felix Kratz, Andre Warnecke
  • Publication number: 20150017177
    Abstract: An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed.
    Type: Application
    Filed: July 25, 2014
    Publication date: January 15, 2015
    Applicant: Durect Corporation
    Inventors: Paul R. Houston, Guohua Chen, Andrew S.K. Luk
  • Publication number: 20150017146
    Abstract: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.
    Type: Application
    Filed: August 7, 2014
    Publication date: January 15, 2015
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Seetharama A. Acharya, Marcos Intaglietta
  • Publication number: 20150011475
    Abstract: The present invention provides a method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion of dry eye severity level 3 or more according to the report of the International Dry Eye WorkShop (DEWS Report) (2007) and a pharmaceutical composition comprising the agent. The present invention further provides a method for the treatment of dry eye and/or corneal and conjunctival lesion of dry eye severity level 3 or more according to DEWS Report (2007) using the agent.
    Type: Application
    Filed: September 25, 2014
    Publication date: January 8, 2015
    Applicant: R-TECH UENO, LTD.
    Inventors: Yukihiko MASHIMA, Akio SIRANITA
  • Publication number: 20150004102
    Abstract: The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, said nanoparticles being based on a vegetable hydrophobic protein, particularly zein, and a water miscible non-volatile organic solvent, particularly propylene glycol. Said nanoparticles can encapsulate or incorporate a product of interest for use in the agricultural, cosmetic, food or pharmaceutical fields.
    Type: Application
    Filed: February 12, 2013
    Publication date: January 1, 2015
    Applicant: BIONANOPLUS, S.L.
    Inventors: Hesham H.A. Salman, Izaskun Goñi Azcárate, Irene Esparza Catalán
  • Publication number: 20150004232
    Abstract: Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications.
    Type: Application
    Filed: April 22, 2014
    Publication date: January 1, 2015
    Applicant: Laboratory Skin Care, Inc.
    Inventor: Zahra Mansouri
  • Publication number: 20140369993
    Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.
    Type: Application
    Filed: January 22, 2013
    Publication date: December 18, 2014
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer, Clive Wilson, Anthony Pettigrew, Annette Hüttig
  • Publication number: 20140363482
    Abstract: The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.
    Type: Application
    Filed: July 1, 2014
    Publication date: December 11, 2014
    Inventors: Hong Guo, Jianbing Chen, Dongling Su, Paul Ashton
  • Patent number: 8906855
    Abstract: A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure and correct hypovolemia.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: December 9, 2014
    Assignee: Vivacelle Bio, Inc.
    Inventor: Cuthbert O. Simpkins
  • Publication number: 20140357567
    Abstract: Provided herein are methods for treating subjects having a cancer, such as a relapsed or refractory solid tumor, wherein the method comprises administering to the subject a cytidine analog. In certain of the methods, the cytidine analog is administered alone or in combination with one or more anti-cancer agents. Also provided are methods for using a cytidine analog, to treat diseases and disorders including disorders related to abnormal cell proliferation, hematologic disorders, and immune disorders, among others. In certain of the methods, the cytidine analog is formulated in an oral dosage form and administered orally.
    Type: Application
    Filed: June 17, 2014
    Publication date: December 4, 2014
    Inventors: Kyle J. MACBETH, Aaron N. NGUYEN, Jorge DIMARTINO
  • Publication number: 20140356439
    Abstract: Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Inventors: Rimona MARGALIT, Dan PEER
  • Patent number: 8901077
    Abstract: The invention relates to a composition comprising albumin and a therapeutic agent, particularly a gene therapy vector. The composition is useful in the treatment of glioma.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: December 2, 2014
    Assignee: Renishaw (Ireland) Limited
    Inventors: Edward White, Steven Streatfield Gill
  • Publication number: 20140348815
    Abstract: Microencapsulation of bioactive and chemical cargo in a stable, cross-linked polymer matrix is presented that results in small particle sizes and is easily scaled-up for industrial applications. A formulation of a salt of an acid soluble multivalent ion, an acid neutralized with a volatile base and one or more monomers that cross-link in the presence of multivalent ions is atomized into droplets. Cross-linking is achieved upon atomization where the volatile base is vaporized resulting in a reduction of the pH of the formulation and the temporal release of multivalent ions from the salt that cross-link the monomers forming a capsule. The incorporation of additional polymers or hydrophobic compounds in the formulation allows control of hydration properties of the particles to control the release of the encapsulated compounds. The operational parameters can also be controlled to affect capsule properties such as particle-size and particle-size distribution.
    Type: Application
    Filed: May 27, 2014
    Publication date: November 27, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Tina Jeoh-Zicari, Herbert B. Scher, Monica C. Santa-Maria, Scott Strobel